# A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

> **NCT07221227** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 1200 (estimated)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Efimosfermin alfa
- **DRUG:** Efimosfermin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07221227
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-24
- **Primary completion:** 2028-03-29
- **Final completion:** 2031-12-12
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221227, "A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07221227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*